Applied Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 25
- Market Cap
- -
Clinical Trials
4
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
AT-007 in Adult Subjects With Classic Galactosemia (CG)
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05418829
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
A phase 2/3 study to evaluate efficacy and clinical benefit of AT-007 with Sorbitol Dehydrogenase (SORD) Deficiency
- Conditions
- Sorbitol Dehydrogenase (SORD) Deficiency
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Applied Therapeutics Inc.
- Target Recruit Count
- 45
- Registration Number
- 2024-518250-16-00
- Locations
- 🇨🇿
Axon Clinical s.r.o., Prague 5, Czechia
🇮🇹IRCCS Foundation Istituto Neurologico Carlo Besta, Milan, Italy
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04902781
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Rare Disease Research Center, Atlanta, Georgia, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT04117711
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
- Conditions
- Diabetic Cardiomyopathies
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Applied Therapeutics, Inc.
- Target Recruit Count
- 675
- Registration Number
- NCT04083339
- Locations
- 🇺🇸
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
🇺🇸University of California, San Diego (UCSD), La Jolla, California, United States
🇺🇸Clinical Trials Research, Lincoln, California, United States
News
BridgeBio's Attruby Approved for ATTR-CM, Cassava's Simufilam Fails in Alzheimer's Trial
BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization.